Veterinary Medicine Research and Development, Pfizer Animal Health, Kalamazoo, MI 49001, USA.
Vet Clin North Am Food Anim Pract. 2010 Mar;26(1):79-88, table of contents. doi: 10.1016/j.cvfa.2009.10.009.
The introduction of newer antimicrobial agents over the past two decades has dramatically improved the treatment of bovine respiratory disease (BRD). In the same time period, the implementation of standardized susceptibility test methods and BRD-specific interpretive criteria has substantially improved the ability to detect clinical resistance in the BRD pathogens. Although overall levels of resistance to the newer antimicrobial agents are generally low, recent data have indicated the potential for emergence and dissemination of a resistant clone in cattle. These data indicate the need for long-term surveillance of antimicrobial resistance in the BRD pathogens and a better understanding of the epidemiology of antimicrobial resistance in these pathogens.
在过去的二十年中，新型抗菌药物的引入极大地改善了牛呼吸道疾病 (BRD) 的治疗效果。在同一时期，标准化药敏试验方法和 BRD 特异性解释标准的实施，极大地提高了检测 BRD 病原体临床耐药性的能力。尽管对新型抗菌药物的总体耐药水平较低，但最近的数据表明，牛中可能会出现和传播耐药克隆。这些数据表明，需要对 BRD 病原体的抗菌药物耐药性进行长期监测，并更好地了解这些病原体的抗菌药物耐药性的流行病学。
